Health topic

Cytomegalovirus (CMV)

Consistent testing for improved patient care

A widespread virus


Cytomegalovirus (CMV) is a common virus found in people of all ages—more than half of all adults have been infected by the age of 40.1 CMV is carried latently for life and can be reactivated.


Weakened immune systems are more susceptible


While the virus generally does not cause problems for those with healthy, functioning immune systems, it can have serious consequences for immunocompromised people.

Some 20%-60% of solid organ transplant recipients develop a symptomatic CMV infection, typically during the first few months after transplantation.2 Patients can be infected through the donor organ, or the virus can be reactivated if previously present.3


CMV assays clinicians can rely on


Reactivation of CMV after a transplant can be detected quickly and treated using antiviral drugs.3 When it comes to successfully managing the infection and helping transplant patients enjoy long, healthy lives, consistency in test results plays a vital role.

Roche is committed to helping deter the spread and reactivation of the Cytomegalovirus and provides WHO-standardized assays to detect and monitor the progression of CMV infections.


Informing effective CMV management


CMV infection is associated with increased long-term overall mortality in patients following transplantation.3 Calibrating and reporting CMV DNA viral load in International Units per milliliter (IU/mL) has improved harmonization of results from different laboratories.4,5 However, management of active CMV infection is still hampered by limited commutability of results between reference materials and clinical samples, and a subsequent lack of evidence-based viral load thresholds.6

Related systems
cobas® 5800 System

The cobas® 5800 System empowers laboratories to balance productivity, efficiency, and potential cost effectiveness with fully automated and standardized workflows, on demand testing and the proven reliability of Roche quality results.

Learn more
cobas® 6800 System

Unparalleled performance, absolute automation, and unmatched flexibility. Meet the needs of molecular testing today and experience the freedom to explore the possibilities for tomorrow.

Learn more
cobas® 8800 System

Unparalleled performance with minimal operator interaction revolutionizes the future of highthroughput applications.

Learn more


  1. Centers for Disease Control and Prevention (CDC). Cytomegalovirus (CMV) and Congenital CMV Infection. Accessed 01/31/2023.
  2. Infections after kidney transplantation. CME Coverage, based on Renal Week 2002: American Society of Nephrology 35th Annual Meeting. Emovon OE, Baillie GM, Rajagopalan PR, Chavin, KD. 
  3. Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo). 2015 Jul; 70(7): 515–523. Accessed 01/31/2023
  4. Virologic Suppression Measured by a Cytomegalovirus (CMV) DNA Test. Clinical Infectious Diseases, Volume 56, Issue 11, 1 June 2013, Pages 1546–1553, Accessed 01/31/2023
  5. An International Multicenter Performance Analysis of Cytomegalovirus Load Tests. Clin Infect Dis. 2013 Feb 1; 56(3): 367–373. Accessed 01/31/2023
  6. Multicenter Evaluation of a Commercial Cytomegalovirus Quantitative Standard: Effects of Commutability on Interlaboratory Concordance. Journal of Clinical Microbiology, Volume 51, Issue 11, November 2013, Pages 3811-3817. Accessed 01/31/2023
Found 0 results in